Cannabidiol improves haloperidol-induced motor dysfunction in zebrafish: a comparative study with a dopamine activating drug
Journal of Cannabis Research volume 5, Article number: 6 (2023)
Cannabidiol (CBD) extracted from the cannabis plant is believed to have a medicinal value due to its neuroprotective effect via anti-inflammatory and antioxidant action. Recent behavioral studies in rats have reported that CBD mediates serotonin (5-HT1A) receptor action to improve motor dysfunction induced by dopamine (D2) receptor blockade. In particular, its effect on D2 receptor blockade in the striatum is an important function associated with neurological disorders resulting from various extrapyramidal motor dysfunctions. Dopaminergic neurodegeneration associated with this site is known for inducing Parkinson’s disease (PD), which often affects the elderly. It is also known to cause drug-induced Parkinsonism. This study examines the ameliorating effect of CBD, which does not act directly on D2 receptors, against drug-induced motor dysfunction induced by the antipsychotic drug (haloperidol).
We created a drug-induced Parkinsonism model in zebrafish larvae using an antipsychotic drug (haloperidol). We evaluated the distance traveled and repetitive light-stimulation response. Furthermore, we examined whether administration of several concentrations of CBD ameliorates symptoms of the Parkinsonism model and compared its effects with those of antiparkinsonian drug ropinirole.
CBD concentrations equal to half of haloperidol’s resulted in an almost complete reversal of haloperidol-induced motor dysfunction, as measured by the distance traveled by the zebrafish and their response to light-stimulus. While ropinirole also significantly reversed haloperidol’s effects at the same concentration as CBD, CBD was more effective than ropinirole.
CBD-induced motor dysfunction improvement via D2 receptor blockade is a potential novel mechanism for the treatment of haloperidol-induced motor dysfunction.
Cannabinoids are chemical components extracted from cannabis plants. They are widely used globally as luxury goods, similar to cigarettes and alcohol, and as medicines, and their various pharmacological effects have been elucidated in previous researches (Gamelin et al. 2020; Oomen et al. 2018). Cannabidiol (CBD), unlike delta-9-tetrahydrocannabinol (THC), has relatively low psychological and addictive effects (Gamelin et al. 2020) and exhibits anti-inflammatory and antioxidant effects on nerve cells. Owing to its protective ability, research on the efficacy of CBD administration as an epilepsy treatment is in progress (Devinsky et al. 2017; Ferreira-Junior et al. 2020; Jose et al. 2018; Cascio and Pertwee 2014). However, many factors remain unclear because the potential effects of cannabinoids on neurotransmission and pharmacological effects on motor function have not been fully elucidated (Campos et al. 2016). Nevertheless, understanding the cannabinoid system in zebrafish could help establish a basis for investigating the effects of cannabinoids in humans (Bailone et al. 2022).
Our previous study revealed various factors affecting the mortality rate and toxicity associated with the use of synthetic cannabinoids (Hasumi et al. 2020). A significant result was the finding that administration of CBD improves motor function to its original state when motor dysfunction is induced by the synthetic cannabinoid WIN55,212-2 R-(+)-[2,3-Dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2.3-de]-1,4-benzoxazin-6-yl]-(1-naphthalenyl)methanone monomethanesulfonate). WIN55,212-2, which showed the same pharmacological action as THC in a previous study (Lawston et al. 2000), induces more behavioral abnormalities than CBD, is highly toxic, and can even cause sudden death upon intake. Understanding the inhibitory effect of CBD against WIN55,212-2 may help unravel CBD’s molecular function. Furthermore, CBD activates the serotonin 1A receptor (or 5-HT1A receptor) (Espejo-Porras et al. 2013), which is known to improve motor dysfunction due to striatal dopamine (D2) receptor inhibition induced by haloperidol to create catalepsy symptoms (Andreza et al. 2016; Gomes et al. 2013). The striatal D2 receptor in the basal ganglia is an important protein associated with Parkinson’s disease (PD) (Patricio et al. 2020).
PD is an extrapyramidal disorder causing involuntary movements, such as those observed in Huntington’s disease, catalepsy, and dyskinesia (Ferreira-Junior et al. 2020; Khisti et al. 1997; Taherianfard et al. 2020; Schmidt and Beninger 2006; Jamwal and Kumar 2019). PD is common among the elderly worldwide and is a serious progressive neurodegenerative disease (Mhyre et al. 2012). A syndrome that causes symptoms similar to PD is called Parkinsonism (Hayes 2019). It has various causes; however, inhibition of dopamine neurotransmission is implicated (Bay Kønig et al. 2019). Antipsychotic drugs used in the treatment of schizophrenia, such as haloperidol (HAL), block dopamine receptors and cause drug-induced Parkinsonism as a side effect (Brigo et al. 2014; Sharma et al. 2018). Therefore, animal models of HAL induction are suitable for assessing the motor functions of Parkinsonism (Waku et al. 2021).
In this study, administration of HAL to zebrafish artificially caused drug-induced Parkinsonism, and CBD was simultaneously administered to determine the improvement in motor dysfunction induced by D2 receptor inhibitory action. Zebrafish were used in this study because they are easy to handle, easy to observe due its transparency, economical, and lay many eggs simultaneously; moreover, their embryos develop quickly (Makhija and Jagtap 2014; Vaz et al. 2018). For verification of motor dysfunction, the amount of exercise based on the total distance traveled, along with the behavior pattern peculiar to zebrafish in response to light stimulation, were measured for a more comprehensive evaluation. In addition, an anti-Parkinsonian drug (Ropinirole) having a D2 receptor activating effect was administered separately, and the superiority or inferiority of improvement in comparison to that induced by CBD was verified.
The experiments were performed according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication 85–23, revised 1996) and in accordance with the zebrafish experimental guide. The Experimental Animal Committee of Tokyo Medical University approved all experiments (approval number: H30-0020, R1-0114, R2-0037). Healthy, adult zebrafish (Danio rerio; purchased from Kamihata Fish Industries Ltd., Tokyo, Japan) were raised in aerated breeding units at a density of 2–3 fish per liter in dechlorinated municipal breeding water supplied by a recirculating water system and fed flake food twice daily. Fish were housed under the following conditions: pH, 7.5–8.0; conductivity, 300–500 μS/cm; temperature, 26–28 °C; and provision of light (8 AM to 10 PM) for 14 h and 10 h of darkness. To produce embryos, male and female zebrafish were paired in the evening, and fertilized embryos were collected and placed in petri dishes with fresh water. Embryos were transferred to a 28°C incubator on a 14:10 h light:dark cycle until 6 days post fertilization (6 dpf). Exposed embryos were screened to assess overall health, and dead embryos were removed on a daily basis.
HAL (Sigma-Aldrich, St. Louis, MO) was diluted with 0.05% dimethyl sulfoxide (DMSO; Dojindo Laboratories, Japan) in sterile saline (vehicle). The drug is a traditional antipsychotic agent used primarily to treat schizophrenia and other psychoses (Gomes et al. 2013; Vaz et al. 2018; Magno et al. 2015; Bruni et al. 2016) by relieving the symptoms of delusions and hallucinations commonly associated with schizophrenia. Haloperidol competitively blocks post-synaptic dopamine D2 receptors, eliminating dopamine neurotransmission while partially inhibiting 5-hydroxy-tryptamine (5-HT2) and α1-receptors. However, there is negligible activation of dopamine D1-receptors (Seibt et al. 2010).
CBD (Cayman Chemical, Ann Arbor, MI) was diluted with 0.05% methanol and sterile saline. CBD, one of the major compounds present in the marijuana (C. sativa) plant, has some medicinal properties; however, its mechanism is not well known (Andreza et al. 2016; Jeong et al. 2019).
Ropinirole hydrochloride (ROP; KYOWA Pharmaceutical Industry Co., Ltd, Osaka, Japan) was diluted with 0.05% dimethyl sulfoxide (DMSO; Dojindo Laboratories, Kumamoto, Japan) and sterile saline. The drug is a novel non-ergoline dopamine agonist, has selective affinity for dopamine D2 receptors, and is indicated for the treatment of early and advanced Parkinson’s disease (Pahwa et al. 2004).
Light and dark test
Previous studies have evaluated locomotion with light stimuli using zebrafish (Magno et al. 2015; Irons et al. 2013; Connors et al. 2014; Liu et al. 2017). During evaluation of abnormal behavior, more comprehensive insights can be gained, not only by determining the levels of activity, but also via assessment of normal behavioral patterns and changes in these patterns attributable to drug effects. Considering that zebrafish display higher locomotor activity in the dark than in the light, the light and dark test is often used to analyze changes in fish locomotor activity and behavioral patterns because of drug effects (Basnet et al. 2019; de Esch et al. 2012). Evaluations based exclusively on the parameters of distance, speed, and duration of movement provide an insufficient assessment of drug effects; thus, we also compared behavioral patterns using the repeated light and dark test.
Zebrafish larvae (6 dpf) were maintained in 96-well microtiter plates (one larva/well) (IWAKI Co. Ltd. Tokyo, Japan) filled with 300 μL breeding water per well. Locomotor activity was assessed after HAL (10 mg/L) induction, and CBD and ROP at 0.5, 1, 5, and 10 mg/L (16 larvae/group) were added directly into the water in the well. Simultaneous HAL+CBD treatments of 10 + 0.5, 10 + 1, 10 + 5, 10 + 10 mg/L (16 larvae/group) and HAL + ROP treatments of 10 + 0.5, 10 + 1, 10 + 5, 10 + 10 mg/L (16 larvae/group) were also assessed in trial 1 (n=192) (Gamelin et al. 2020). Furthermore, we also assessed the only CBD treatments of 1, 5, 10 mg/L (16 larvae/group) and the only ROP treatments of 1, 5, 10 mg/L (16 larvae/group) in trial 2 (n=144) (Oomen et al. 2018). The drug concentrations were determined in advance based on previous studies (Hasumi et al. 2020; Ellis et al. 2018).
Once the final concentration of the drug and the larvae were placed in the well, the distance traveled and the motion measurement at the time of illumination with bright (i.e., light-on periods) or infrared (i.e., darkness or light-off periods) light exposure by repeated light stimulation were examined until the end without replacing the larvae, water, and chemicals.
The light intensity used during the light-on period was 5000 lx, whereas under infrared illumination, the intensity was 0 lx. Fish were subjected to alternating (six times) light and dark exposure at 5-min intervals to determine differences in locomotor activities and response (Hasumi et al. 2020; Basnet et al. 2019; Yang et al. 2017; Maeda et al. 2021a; Maeda et al. 2021b). Drug effects were measured for 1 h using Danio Vision XT and Ethovision XT 11.5 (Noldus Information Technology, Wageningen, The Netherlands) (Maeda et al. 2018). Danio Vision is a high-throughput system that facilitates analysis of the behavioral responses of treated zebrafish and can simultaneously track up to 96 individuals (Maeda et al. 2021a) using the associated software. We examined the total distance traveled and movement response to the light and dark test. To measure spontaneous motion, by using a tracking system, the movement distance of the larvae in each light and dark time zone was tracked and the distance traveled in all time zones was summed.
Regarding the duration of drug treatment, the acclimation time was set at 30 min (Hasumi et al. 2020), and was followed by a total of six times as one set of light and dark times at 5-min intervals. Therefore, the total exposure time was 90 min. According to previous studies, the concentration of methanol, which is the medium of CBD, is 0.05% (Hasumi et al. 2020). However, this concentration has no effect in research (Hasumi et al. 2020).
One-way analysis of variance (ANOVA) was used for statistical comparisons of the recorded observational data, followed by pairwise post-hoc comparisons using the Tukey–Kramer test. The data were analyzed using the Tukey–Kramer at a confidence level of 95%.
Data are presented as means ± standard errors of the mean (SEMs) of at least three independent experiments. Statistical analysis was performed in GraphPad Prism 6 for Windows version 6.05 (GraphPad Software, San Diego, CA, USA).
One-way ANOVA indicated that there were significant effects on total distance traveled (F=6.098, p<0.0001) in trial 1 (n=192), and there were also significant effects on total distance traveled (F=22.03, p<0.0001) in trial 2 (n=144).
HAL-induced motor-dysfunction animal model (HAL 10 mg/L)
First, we compared the total distance traveled between the control and HAL-treated groups at different doses (0.5, 1, 5, 10 mg/L). The HAL-treated group displayed the strongest effect at 10 mg/L (Fig. 1a). We also compared the light (ON)/dark (OFF)-stimulation response between the control and HAL (10 mg/L)-treated groups to verify whether 10 mg/L of HAL was adequate to reproduce the HAL-induced motor-dysfunction animal model. Zebrafish larvae normally exhibit hyperactivity in the dark and hypoactivity in light. We rotated between light and dark conditions every 5 min in 1-h trials. In the dark, control locomotor activity increased sharply, whereas light resulted in decreased activity. Comparing the control and HAL-10 mg/L groups, no significant difference was observed during lights ON, but the reactivity during lights OFF from the first to the sixth iteration was significantly reduced (p<0.01; Fig. 1b). Hence, 10 mg/L of HAL clearly decreased both activity and stimulus response, compared to the control group, and caused motor dysfunction-like symptoms.
Effect of CBD on the motor-dysfunction animal model
When CBD was administered at 1, 5, and 10 mg/L to the motor-dysfunction animal group (HAL-10 mg/L), the distance traveled was clearly improved at CBD 5 mg/L compared to the motor-dysfunction animal group (p<0.05; Fig. 2). In addition, there was no significant difference between the HAL 10 mg/L + CBD 1 mg/L, HAL 10 mg/L + CBD 5 mg/L, HAL 10 mg/L + CBD 10 mg/L and the control and DMSO groups (Fig. 2).
Activity under light stimulation decreased significantly in the HAL 10 mg/L + CBD 1 mg/L group compared to the control group in the second light condition (p<0.05) and the sixth dark condition (p<0.01; Fig. 3a). The HAL 10 mg/L + CBD 5 mg/L group showed no significant difference in all light and dark conditions compared to the control group (Fig. 3b). In the HAL 10 mg/L + CBD 10 mg/L group, the response was enhanced during the first light condition compared to the control group; however, the response significantly decreased during all dark periods (Fig. 3c).
Comparing HAL 10 mg/L and HAL 10 mg/L + CBD on the light/dark-stimulation experiment, the HAL 10 mg/L + CBD 1 mg/L group showed increased activity during the second to fifth dark periods, which was a significantly improved response compared to that of the motor-dysfunction animal group (Fig. 3d).
The HAL 10 mg/L + CBD 5 mg/L group had a significantly enhanced response during the sixth light condition compared to the motor-dysfunction animal group; however, the response was significantly improved during all dark conditions (Fig. 3e). In addition, the response of the HAL 10 mg/L + CBD 10 mg/L group was enhanced only in the first light condition (p<0.05) and in the third dark condition (p<0.01) compared to that of the motor-dysfunction animal group (Fig. 3f).
The effect of ROP on the motor-dysfunction animal model
Similarly, when ROP was administered at 1, 5, and 10 mg/L to the motor-dysfunction animal group (HAL 10 mg/L), the distance traveled was clearly improved with ROP 10 mg/L compared to the motor-dysfunction animal group (p<0.01; Fig. 2). In addition, there was no significant difference between the HAL 10 mg/L + ROP 1 mg/L, HAL 10 mg/L + ROP 5 mg/L, and HAL 10 mg/L + ROP 10 mg/L groups compared to the control and DMSO groups (Fig. 2).
Although the response of the HAL 10 mg/L + ROP 1 mg/L group was enhanced compared with that of the control group in the first light period (p<0.05), the responses were significantly decreased during the second to sixth dark periods (p<0.01; Fig. 4a).
In the HAL 10 mg/L + ROP 5 mg/L group, the response was significantly enhanced in all lights-ON conditions compared to the control group. However, the response was significantly decreased in all lights-OFF conditions (Fig. 4b). In the HAL 10 mg/L + ROP 10 mg/L group, there was no significant difference in all dark conditions compared to the control group; however, the response was enhanced during the first to fifth light conditions (p<0.01; Fig. 4c). Comparison of the effects of the HAL 10 mg/L and HAL 10 mg/L + ROP groups on the light/dark-stimulatory response revealed that the effects of the HAL 10 mg/L + ROP 1 mg/L group were significantly enhanced only during the first light condition compared with those of the motor-dysfunction animal group (p<0.05; Fig. 4d). The HAL 10 mg/L + ROP 5 mg/L group had a significantly enhanced response in all lights-ON periods compared to the motor-dysfunction animal group (p<0.01; Fig. 4e). In the HAL 10 mg/L + ROP 10 mg/L group, the response was improved during all dark periods compared to that of the motor-dysfunction animal group; however, the response was enhanced in all light periods (p<0.01; Fig. 4f).
Effect of CBD on normal animal model compared to the motor-dysfunction animal model
When CBD was administered at doses of 1, 5, and 10 mg/L to the normal animal group, the distance traveled clearly showed that all groups were different from the motor-dysfunction animal group (p<0.01; Fig. 5). In addition, there was a significant difference between the CBD 10 mg/L and the control group (p<0.01; Fig. 5).
Activity under light/dark stimulation did not decrease significantly in the CBD 1 mg/L and CBD 5 mg/L groups compared to control (p<0.05, p<0.01; Fig. 6a, b); however, activity under dark conditions decreased significantly in the CBD 10 mg/L group compared to control (p<0.05, p<0.01; Fig. 6c).
Comparing HAL 10 mg/L and CBD on the light/dark-stimulation experiment, the CBD 1 mg/L and CBD 5 mg/L groups showed significant differences especially under dark stimulation (p<0.05, p<0.01; Fig. 7a, B). The CBD 10 mg/L group had significantly different responses during the first through fourth light/dark conditions compared to those of the motor-dysfunction animal group (p<0.05, p<0.01; Fig. 7c).
The effect of ROP on normal animal model compared to the motor-dysfunction animal model
When ROP was administered at 1, 5, and 10 mg/L to the normal animal group, the distance traveled clearly showed that all groups were different from the motor-dysfunction animal group (p<0.05, p<0.01; Fig. 5). In addition, there was a significant difference between ROP 10 mg/L compared to the control (p<0.01; Fig. 5).
Comparing the ROP 1 mg/L and 5 mg/L groups to the normal animal group, the distance traveled under the first through fourth light periods was clearly enhanced compared to CNTL (p<0.05, p<0.01; Fig. 6a, b); however, the response of the ROP 10 mg/L group decreased in all dark conditions compared with that of the CNTL (p<0.01; Fig. 6c). In addition, there was a significant difference between ROP 10 mg/L compared to the motor-dysfunction animal group except for the sixth light period (Fig. 7d, e); however, the response of the ROP 10 mg/L group was different only in the second light and third light/dark conditions compared with that of the motor-dysfunction animal group (p<0.05, p<0.01; Fig. 7f).
The purpose of this study is to examine whether CBD has an ameliorating effect on HAL-induced motor dysfunction, using zebrafish, and its effect was compared to that of an anti-PD drug. Before examining the effect of CBD, we needed a HAL-induced motor-dysfunction animal model; hence, we started by trying to reproduce one.
Normal zebrafish display low activity levels during light periods, while in the dark, they are hyperactive (Maeda et al. 2021b). This property can be used to investigate the effects of each drug on dopamine receptors in zebrafish. Therefore, when HAL, CBD, and ROP were administered individually to zebrafish, a significant decrease in activity was observed starting from 5–10 mg/L for HAL, and a similar decrease was observed in response to both the light and dark conditions at the 10-mg/L dose. Therefore, HAL 10 mg/L was used as the standard for movement disorders. There was no significant change in ROP and CBD at the same concentration compared to the normal group, but as with the concentration of 10 mg/L, activity decreased as the concentration was as high as that of HAL. However, for repetitive photostimuli, a unique pattern was confirmed: CBD decreased reactivity from the 10 mg/L dark band, while ROP increased at light for 1–5 mg/L, but conversely decreased at dark at 10 mg/L. Thus, it is important to understand the characteristics of the behavior pattern of each drug in light and dark. Confirming abnormal patterns of activity (hypoactivity and hyperactivity) will set a standard for further investigation of the synergistic effects between drugs. It can also guide future research on developing a zebrafish model for studying movement disorders.
A comparison between the control (or normal) and HAL 10 mg/L groups revealed a significant difference in the total distance traveled and activity during lights-OFF; however, there was no significant difference during lights-ON. In the group with D2 receptor inhibition, decreased response during lights-ON was not different from that in the normal group. However, motor dysfunction was confirmed, in which the reactivity was significantly reduced even during the dark periods.
This experiment shows that a HAL-induced motor-dysfunction animal model can be reproduced by administration of HAL 10 mg/L and the total distance traveled and the light/dark-stimulation response could be measured. Next, as a result of administering CBD and ROP of each concentration group to this Parkinsonism model, the CBD 5 mg/L and ROP 10 mg/L groups showed a significant improvement in the total distance traveled compared to the Parkinsonism model group, respectively. From this result alone, the improvement in momentum in both cases could be seen; however, the results were significantly different between the CBD 5 mg/L and ROP 10 mg/L groups, in terms of the light-stimulation response. In an experiment comparing the normal and HAL 10 mg/L groups, activity was significantly different during dark periods, but not during light period. In experiments using CBD, administration of CBD 5 mg/L to the HAL-induced motor-dysfunction model group showed no significant difference during the light periods. However, activity was improved during dark periods. In experiments using ROP, administration of ROP 10 mg/L improved activity in the dark, but the fact that activity was significantly higher in the light was clearly an abnormal increase compared to the normal group. Therefore, examination of the total distance traveled and light-stimulation response showed that CBD 5 mg/L has a higher efficacy on the HAL-induced motor-dysfunction model group than ROP 10 mg/L. Specifically, at 5 mg/L, the ameliorating effect of CBD required approximately half of the HAL concentration (10 mg/L) and was more effective than the other CBD concentration groups (1 and 10 mg/L). Furthermore, although administration of ROP showed a concentration-dependent improvement in the HAL-induced motor-dysfunction model group, CBD 5 mg/L made the zebrafish behave more normally than the various ROP concentrations (1, 5, 10 mg/L). Therefore, the movement disorder caused by the pharmacological effect of HAL (at 10 mg/L) could be improved most by half the concentration of CBD (5 mg/L), and the D2 activation effect exerted by CBD was stronger than the D2 inhibitory effect exerted by HAL.
The effect of CBD 5 mg/L was higher than that of ROP at the same concentration (5 mg/L). ROP was more effective at 5 mg/L and less effective at 10 mg/L. Hence, CBD might be better than ROP and may show efficacy as an anti-PD drug. 5-HT1A receptors are deeply involved in serotonin regulation but are also implicated in the regulation of dopamine levels in the brain (Hu 2016; Di Giovanni et al. 2008). In fact, some reports have suggested that cannabis improves Parkinsonism (Venderová et al. 2004); hence, a future pharmacological challenge is directly influencing motor dysfunction promoted by drug-induced D2 receptor blockade. It is necessary to verify whether the mediation effect of 5-HT1A receptor activation of CBD has a higher improvement effect than that of dopamine D2 receptor activation. Concerning drug toxicity, morphological changes or toxicity due to HAL, CBD, or ROP have not been identified with respect to abnormalities in activity with high doses.
Similarly, using zebrafish, many research papers on drug-induced catalepsy symptoms have evaluated behavioral actions based on decreasing duration of movement due to D2 receptor blocking, including the delay in start time and the total distance travelled (Flinn et al. 2008; Stewart and Kalueff 2014; Tierney 2011). Therefore, in this study, not only the amount of exercise (total distance traveled), but also the normal and abnormal movement patterns, were compared to evaluate the activity and motor function as a whole.
The behavioral characteristics of zebrafish are important, and in normal larvae, their activity decreases under bright light stimulation and increases in dark conditions. This is a normal behavioral pattern and an indicator of the reaction (Hasumi et al. 2020; de Esch et al. 2012). The total distance traveled within the measurement time can determine the strength of the overall activity, but not the abnormality of the behavior pattern. For example, if the total distance traveled under the influence of drug A is the same as that traveled by an untreated zebrafish, but the total distance traveled under the influence of drug B is significantly reduced, it can be considered that motor function is affected by drug B but not by drug A. However, when comparing behavioral patterns, if remarkable abnormal behavior is always observed with drug A, it cannot be stated that drug A has no effect on motor function. Furthermore, to date, it is believed that cannabinoids and dopamine are closely related (Covey et al. 2017); however, the degree of recovery of drug-induced Parkinsonism-like symptoms by CBD to a state close to normal is yet to be determined. In this study, we were able to verify the effect of CBD more specifically by pursuing the concentration ratio at which HAL and CBD become antagonistic and by comparing them with anti-PD drugs (ROP) of the same concentration.
There have been many pharmacological studies on dopamine in zebrafish, and it has been found that motor dysfunction due to dopamine receptor inhibitory action is similar to that of humans (Vaz et al. 2018). In addition, there are comparative studies of zebrafish models and rodent models in Parkinson's disease studies (Makhija and Jagtap 2014), but the zebrafish model as a whole has not yet been established. Interactions between dopamine receptors and cannabinoids in rodents have also been reported in several papers (Andreza et al. 2016; Gomes et al. 2013).Although it has been elucidated that CBD's neuroprotective effect (Patricio et al. 2020) and dopamine receptor activation via serotonin receptors contribute to improved motor function (Espejo-Porras et al. 2013; Andreza et al. 2016; Gomes et al. 2013), it is necessary to verify the same in zebrafish in the future.
Clinical application-focused research on CBD is currently progressing dramatically, and the results of this study indicate that CBD at approximately half the concentration of haloperidol, which has a D2 blocking effect, ameliorates the symptoms. Our findings are only the tip of the iceberg. However, the finding that CBD, which has no direct D2 receptor action, is effective against Parkinsonism-like symptoms induced by inhibition of D2 receptor action will change our considerations concerning cannabinoids in the future.
To date, CBD research has been conducted to determine its antiepileptic action or antipsychotic side effects (Devinsky et al. 2017; Andreza et al. 2016); however, CBD is also expected to have a therapeutic effect on neurodegenerative diseases, such as Parkinson’s and Alzheimer’s diseases, due to receptor blockade and the neuroprotective effect of anti-inflammation and anti-oxidation (Patricio et al. 2020; Cooray et al. 2020; Crippa et al. 2018). However, the applied research for neuromotor and neurodegenerative diseases by CBD for the purpose of full-scale treatment has not yet reached the scale of clinical trials. Hence, this research is at a stage where further basic experiments need to be conducted in the future. This study provides basic research data on the improvement effect of CBD on dopamine receptor-induced motility disorder in the striatum.
Availability of data and materials
Data and materials are available upon request to the corresponding author.
Analysis of variance
Andreza BS, Felipe VG, Elaine AD, Francisco SG. Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors. Behav Brain Res. 2016;309:22–8.
Bailone RL, Fukushima HCS, De Aguiar LK, Borra RC. The endocannabinoid system in zebrafish and its potential to study the effects of Cannabis in humans. Lab Anim Res. 2022;38:1–12.
Basnet RM, Zizioli D, Taweedet S, Finazzi D, Memo M. Zebrafish larvae as a behavioral model in neuropharmacology. Biomedicines. 2019;7:3390.
Bay Kønig AB, Ciriachi C, Gether U, Rickhag M. Chemogenetic targeting of dorsomedial direct-pathway striatal projection neurons selectively elicits rotational behavior in mice. Neuroscience. 2019;401:106–16.
Brigo F, Erro R, Marangi A, Bhatia K, Tinazzi M. Differentiating drug-induced parkinsonism from Parkinson’s disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord. 2014;20:808–14.
Bruni G, Rennekamp AJ, Velenich A, McCarroll M, Gendelev L, Fertsch E, et al. Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds. Nat Chem Biol. 2016;12:559–66.
Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016;112:119–27.
Cascio MG, Pertwee RG. Known pharmacological actions of nine nonpsychotropic phytocannabinoids. In: Pertwee RG, editor. Handbook of cannabis. Oxford: Oxford University Press; 2014. p. 137–56.
Connors KA, Valenti TW, Lawless K, Sackerman J, Onaivi ES, Brooks BW, et al. Similar anxiolytic effects of agonists targeting serotonin 5-HT1A or cannabinoid CB receptors on zebrafish behavior in novel environments. Aquat Toxicol. 2014;151:105–13.
Cooray R, Gupta V, Suphioglu C. Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s diseases: a review. Mol Neurobiol. 2020;57:4878–90.
Covey DP, Mateo Y, Sulzer D, Cheer JF, Lovinger DM. Endocannabinoid modulation of dopamine neurotransmission. Neuropharmacology. 2017;124:52–61.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol. 2018;9:2009.
de Esch C, van der Linde H, Slieker R, Willemsen R, Wolterbeek A, Woutersen R, et al. Locomotor activity assay in zebrafish larvae: influence of age, strain and ethanol. Neurotoxicol Teratol. 2012;34:425–33.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–20.
Di Giovanni G, Di Matteo V, Pierucci M, Esposito E. Serotonin-dopamine interaction: electrophysiological evidence. Prog Brain Res. 2008;172:45–71.
Ellis LD, Berrue F, Morash M, Achenbach JC, Hill J, McDougall JJ. Comparison of cannabinoids with known analgesics using a novel high throughput zebrafish larval model of nociception. Behav Brain Res. 2018;337:151–9.
Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García C. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. 2013;75:155–63.
Ferreira-Junior NC, Campos AC, Guimarães FS, Del-Bel E, da Zimmermann RM, Brum Junior L, et al. Biological bases for a possible effect of cannabidiol in Parkinson’s disease. Braz J Psychiatry. 2020;42:218–24.
Flinn L, Bretaud S, Lo C, Ingham PW, Bandmann O. Zebrafish as a new animal model for movement disorders. J Neurochem. 2008;106:1991–7.
Gamelin FX, Cuvelier G, Mendes A, Aucouturier J, Berthoin S, Di Marzo V, et al. Cannabidiol in sport: Ergogenic or else? Pharmacol Res. 2020;156:104764.
Gomes FV, Del Bel EA, Guimarães FS. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:43–7.
Hasumi A, Maeda H, Yoshida KI. Analyzing cannabinoid-induced abnormal behavior in a zebrafish model. PLoS One. 2020;15:e0236606.
Hayes MT. Parkinson’s disease and parkinsonism. Am J Med. 2019;132:802–7.
Hu H. Reward and aversion. Annu Rev Neurosci. 2016;39:297–324.
Irons TD, Kelly PE, Hunter DL, Macphail RC, Padilla S. Acute administration of dopaminergic drugs has differential effects on locomotion in larval zebrafish. Pharmacol Biochem Behav. 2013;103:792–813.
Jamwal S, Kumar P. Insight into the emerging role of striatal neurotransmitters in the pathophysiology of Parkinson’s disease and Huntington’s disease: a review. Curr Neuropharmacol. 2019;17:165–75.
Jeong S, Yun HK, Jeong YA, Jo MJ, Kang SH, Kim JL, et al. Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. Cancer Lett. 2019;447:12–23.
Jose A, Chaitanya MVNL, Kannan E, Madhunapantula SV. Tricaproin isolated from Simarouba glauca inhibits the growth of human colorectal carcinoma cell lines by targeting Class-1 histone deacetylases. Front Pharmacol. 2018;9:127.
Khisti RT, Mandhane SN, Chopde CT. Haloperidol-induced catalepsy: a model for screening antidepressants effective in treatment of depression with Parkinson’s disease. Indian J Exp Biol. 1997;35:1297–301.
Lawston J, Borella A, Robinson JK, Whitaker-Azmitia PM. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212–2. Brain Res. 2000;877:407–10.
Liu Y, Ma P, Cassidy PA, Carmer R, Zhang G, Venkatraman P, et al. Statistical analysis of zebrafish locomotor behaviour by generalized linear mixed models. Sci Rep. 2017;7:2937.
Maeda H, Fukushima N, Hasumi A. Standardized method for the assessment of behavioral responses of zebrafish larvae. Biomedicines. 2021b;9:884.
Maeda H, Hasumi A, Yoshida K. Caffeine-induced bradycardia, death, and anxiety-like behavior in zebrafish larvae. Forensic Toxicol. 2021a;39:427–36.
Maeda H, Nagashima E, Hayashi YK, Kikura-Hanajiri R, Yoshida K. MDMB-CHMICA induces thrashing behavior, bradycardia, and slow pressor response in a CB1- and CB2-receptor-dependent manner in conscious rats. Forensic Toxicol. 2018;36:313–9.
Magno LDP, Fontes A, Gonçalves BM, Gouveia A. Pharmacological study of the light/dark preference test in zebrafish (Danio rerio): Waterborne administration. Pharmacol Biochem Behav. 2015;135:169–76.
Makhija DT, Jagtap AG. Studies on sensitivity of zebrafish as a model organism for Parkinson’s disease: Comparison with rat model. J Pharmacol Pharmacother. 2014;5:39–46.
Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson’s disease. Subcell Biochem. 2012;65:389–455.
Oomen PP, van Hell HH, Bossong MG. The acute effects of cannabis on human executive function. Behav Pharmacol. 2018;29:605–16.
Pahwa R, Lyons KE, Hauser RA. Ropinirole therapy for Parkinson’s disease. Expert Rev Neurother. 2004;4:581–8.
Patricio F, Morales-Andrade AA, Patricio-Martínez A, Limón ID. Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson’s disease. Front Pharmacol. 2020;11:595635.
Schmidt WJ, Beninger RJ. Behavioural sensitization in addiction, schizophrenia, Parkinson’s disease and dyskinesia. Neurotox Res. 2006;10:161–6.
Seibt KJ, Oliveira Rda L, Zimmermann FF, Capiotti KM, Bogo MR, Ghisleni G, et al. Antipsychotic drugs prevent the motor hyperactivity induced by psychotomimetic MK-801 in zebrafish (Danio rerio). Behav Brain Res. 2010;214:417–22.
Sharma AK, Gupta S, Patel RK, Wardhan N. Haloperidol-induced parkinsonism is attenuated by varenicline in mice. J Basic Clin Physiol Pharmacol. 2018;29:395–401.
Stewart AM, Kalueff AV. The behavioral effects of acute Δ9-tetrahydrocannabinol and heroin (diacetylmorphine) exposure in adult zebrafish. Brain Res. 2014;1543:109–19.
Taherianfard M, Riyahi M, Razavi M, Bavandi Z, Eskandari Roozbahani N, Namavari MM. The cataleptic, asymmetric, analgesic, and brain biochemical effects of Parkinson’s disease can be affected by Toxoplasma gondii infection. Biomed Res Int. 2020;2020:2546365.
Tierney KB. Behavioural assessments of neurotoxic effects and neurodegeneration in zebrafish. Biochim Biophys Acta. 2011;1812:381–9.
Vaz RL, Outeiro TF, Ferreira JJ. Zebrafish as an animal model for drug discovery in Parkinson’s disease and other movement disorders: A systematic review. Front Neurol. 2018;9:347.
Venderová K, Růzicka E, Vorísek V, Visnovský P. Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Mov Disord. 2004;19:1102–6.
Waku I, Magalhães MS, Alves CO, de Oliveira AR. Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies. Eur J Neurosci. 2021;53:3743–67.
Yang X, Lin J, Peng X, Zhang Q, Zhang Y, Guo N, et al. Effects of picrotoxin on zebrafish larvae behaviors: A comparison study with PTZ. Epilepsy Behav. 2017;70:224–31.
The authors would like to thank the Department of Forensic Medicine at Tokyo Medical University for their support. This study was supported by the Japan Society for the Promotion of Science (16K09218: Hideyuki Maeda).
This research received no external funding.
Ethics approval and consent to participate
All experiments were approved by the Experimental Animal Committee of Tokyo Medical University (approval number: H30-0020, R1-0114, R2-0037).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hasumi, A., Maeda, H. Cannabidiol improves haloperidol-induced motor dysfunction in zebrafish: a comparative study with a dopamine activating drug. J Cannabis Res 5, 6 (2023). https://doi.org/10.1186/s42238-023-00177-w
- D2 receptor
- Light and dark zones